Spondylarthritis: Clinical Trials

207 trials for Spondylarthritis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

151 completed, 19 active not recruiting, 11 terminated, 9 unknown. 207 Phase 3, 15 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3207Completed 151, Active not recruiting 19, Terminated 11, Unknown 9, Recruiting 8, Not yet recruiting 4, Withdrawn 4, Enrolling by invitation 1
Phase 215Unknown 7, Completed 4, Recruiting 2, Not yet recruiting 1, Terminated 1

Follow Spondylarthritis: new trials by email Literature Review of Spondylarthritis trials Research Report on Spondylarthritis

Trials (filtered) newest first · largest first

All 207 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)
Placebo, Zasocitinib - Psoriatic Arthritis
Phase 3Not yet recruitingTakeda6442027-01-112026-10-27
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease
Phase 3Not yet recruitingBristol-Myers Squibb23002026-12-312026-09-03
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Zasocitinib - Psoriatic Arthritis
Phase 3RecruitingTakeda11822026-03-112026-11-12
A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
608, Placebo - Axial Spondyloarthritis, Non-Radiographic
Phase 3Not yet recruitingSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.3802026-03-092026-01-16
Efficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis
Xeligekimab injection - Nr-axial Spondyloarthritis, Non-Radiographical Axial Spondyloarthritis
Phase 2 / Phase 3Not yet recruitingLingli Dong402026-01-312026-01-14
A Study of Picankibart in Patients With Active Psoriatic Arthritis
Placebo, Picankibart - Psoriatic Arthritis
Phase 2 / Phase 3RecruitingInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.2222025-12-182026-03-20
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
Sonelokimab - Arthritis, Psoriatic
Phase 3Enrolling by invitationMoonLake Immunotherapeutics AG15602025-11-132026-11-12
A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)
608 dose, Placebo - Ankylosing Spondylitis
Phase 3RecruitingSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.5002025-11-072025-12-10
A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis
LNK01001, Placebo - Ankylosing Spondylitis
Phase 3RecruitingLynk Pharmaceuticals Co., Ltd3522025-08-292026-11-12
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Zasocitinib, Placebo - Psoriatic Arthritis
Phase 3Active not recruitingTakeda6012025-03-102026-10-14
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Zasocitinib, Active Comparator, Placebo - Psoriatic Arthritis
Phase 3Active not recruitingTakeda15832025-03-032026-11-12
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
Icotrokinra, Placebo, Active reference comparator - Arthritis, Psoriatic
Phase 3Active not recruitingJanssen Research & Development, LLC5522025-02-212026-11-03
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
Icotrokinra, Placebo - Arthritis, Psoriatic
Phase 3Active not recruitingJanssen Research & Development, LLC8132025-01-092026-11-03
A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis
SHR-1314 injection, Placebo - Psoriatic Arthritis
Phase 3Active not recruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.2082024-11-042026-08-06
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Guselkumab - Crohns Disease, Colitis, Ulcerative
Phase 3RecruitingJanssen Research & Development, LLC1962024-10-292026-11-03
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
Bimekizumab, Risankizumab, Placebo - Psoriatic Arthritis
Phase 3CompletedUCB Biopharma SRL5532024-10-212026-09-02
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
Sonelokimab, Placebo - Arthritis, Psoriatic
Phase 3Active not recruitingMoonLake Immunotherapeutics AG9602024-10-152026-11-16
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
Sonelokimab, Placebo, Risankizumab - Arthritis, Psoriatic
Phase 3Active not recruitingMoonLake Immunotherapeutics AG6002024-10-152026-11-16
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Ixekizumab, Tirzepatide - Psoriatic Arthritis, Obesity
Phase 3CompletedEli Lilly and Company2792024-09-242026-05-13
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
bimekizumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
Phase 3Active not recruitingUCB Biopharma SRL892024-07-292026-07-17

Showing 20 of 207. Sign in to see all of them.

Narrower conditions

Arthritis, Psoriatic (105)  ·  Spondylitis, Ankylosing (82)  ·  Axial Spondyloarthritis (26)  ·  Psoriasis (23)  ·  Arthritis (18)  ·  Spondylarthropathies (12)  ·  Non-Radiographic Axial Spondyloarthritis (10)  ·  Arthritis, Rheumatoid (6)  ·  Arthritis, Juvenile (5)  ·  Spondylitis (5)  ·  Inflammation (4)  ·  Joint Diseases (4)  ·  Musculoskeletal Diseases (4)  ·  Skin Diseases (4)

Broader conditions

Bone Diseases (206)  ·  Joint Diseases (203)  ·  Musculoskeletal Diseases (203)  ·  Spinal Diseases (203)  ·  Spondylitis (202)  ·  Spondylarthropathies (193)  ·  Arthritis (189)  ·  Skin and Connective Tissue Diseases (110)  ·  Skin Diseases, Papulosquamous (105)  ·  Skin Diseases (101)  ·  Ankylosis (99)  ·  Psoriasis (82)  ·  Axial Spondyloarthritis (74)  ·  Immune System Diseases (13)

Interventions

secukinumab (29)  ·  Adalimumab (25)  ·  golimumab (14)  ·  Etanercept (13)  ·  Methotrexate (11)  ·  bimekizumab (11)  ·  ixekizumab (11)  ·  Ustekinumab (10)  ·  apremilast (10)  ·  Infliximab (9)  ·  tofacitinib (9)  ·  guselkumab (7)  ·  Certolizumab Pegol (5)  ·  GLPG0634 (5)  ·  risankizumab (5)

Sponsors

Novartis Pharmaceuticals (27)  ·  Janssen Research & Development, LLC (14)  ·  Amgen (11)  ·  UCB Biopharma SRL (11)  ·  Eli Lilly and Company (10)  ·  Pfizer (9)  ·  Abbott (8)  ·  AbbVie (7)  ·  Centocor, Inc. (6)  ·  Biocad (4)  ·  Bristol-Myers Squibb (4)  ·  Gilead Sciences (4)  ·  Merck Sharp & Dohme LLC (4)  ·  Takeda (4)  ·  UCB BIOSCIENCES GmbH (4)

Countries

United States (103)  ·  Germany (88)  ·  Poland (85)  ·  Czechia (78)  ·  Spain (77)  ·  United Kingdom (75)  ·  Canada (72)  ·  Russia (69)  ·  Hungary (62)  ·  France (59)  ·  Belgium (55)  ·  Australia (53)  ·  Bulgaria (50)  ·  Italy (50)  ·  China (42)

Top investigators

Beverly Paperiello (3)  ·  Roman Ivanov, PhD (3)

Results publications

PMID 31203228, PMID 38446397, PMID 37316690, PMID 40194794, PMID 41807031, PMID 41965705, PMID 42386286, PMID 34618347, PMID 35305260, PMID 38488975, PMID 39120849, PMID 33722947, PMID 34795065, PMID 36792107, PMID 39120848, PMID 40241921, PMID 30018799, PMID 30473179, PMID 31077258, PMID 31112005, PMID 31909868, PMID 31964419, PMID 32006348, PMID 32352653, PMID 32816215, PMID 33227175, PMID 33351179, PMID 34536218, PMID 34773130, PMID 34870800, PMID 35393269, PMID 35429281, PMID 36282526, PMID 36526796, PMID 36642439, PMID 36931693, PMID 36958766, PMID 36995469, PMID 37906417, PMID 37982966, PMID 38488976, PMID 38683479, PMID 38754125, PMID 39215949, PMID 39534481, PMID 39624020, PMID 40347389, PMID 40694276, PMID 40875187, PMID 41039829

NIH funding

2015 (12), 2023 (11), 2009 (10), 2016 (9), 2014 (6), 2017 (6), 2019 (6), 2018 (5), 2008 (1), 2025 (1), R21AR053646 (1)